Literature DB >> 3491582

Meningitis due to Haemophilus influenzae resistant to ampicillin and chloramphenicol.

A P Fraise, A C Meeks, J E Richards.   

Abstract

A case of ampicillin and chloramphenicol resistant Haemophilus influenzae meningitis successfully treated with cefotaxime is described.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491582      PMCID: PMC1778100          DOI: 10.1136/adc.61.11.1134

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Haemophilus influenzae type B resistant to ampicillin and chloramphenicol in an orphanage in Thailand.

Authors:  S Simasathien; C Duangmani; P Echeverria
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

2.  Haemophilus influenzae type b resistant to chloramphenicol and ampicillin.

Authors:  J A Sills; P MacMahon; E Hall; T Fitzgerald
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26

3.  Meningitis due to beta lactamase producing type b Haemophilus influenzae resistant to chloramphenicol.

Authors:  R J Garvey; G P McMullin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-22

4.  Rapid detection of chloramphenicol resistance in Haemophilus influenzae.

Authors:  M P Slack; D B Wheldon; D C Turk
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

5.  Moxalactam therapy of Haemophilus influenzae type b meningitis in children.

Authors:  S A Chartrand; M I Marks; R K Scribner; J T Johnston; D F Frederick
Journal:  J Pediatr       Date:  1984-03       Impact factor: 4.406

  5 in total
  4 in total

1.  Cefotaxime versus chloramphenicol for ampicillin-resistant Haemophilus influenzae meningitis. A retrospective study of 62 cases.

Authors:  J R Lapointe; L Chicoine
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

4.  In vitro activity of florphenicol.

Authors:  R Graham; D Palmer; B C Pratt; C A Hart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.